Status:

COMPLETED

Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer

Lead Sponsor:

University Health Network, Toronto

Conditions:

Endometrial Cancer

Sentinel Lymph Node

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

The standard of care for women with high risk endometrial cancer is the removal of all visible lymph nodes in the pelvis and lower abdomen to identify if disease has spread to these areas. It is estim...

Detailed Description

If the SLN can be accurately identified and the detection of metastatic lymph nodes in women with early stage high risk endometrial cancer can be improved then the majority of women could avoid a comp...

Eligibility Criteria

Inclusion

  • Women with endometrial cancer with high risk histologic subtypes including grade 3 endometrioid, carcinosarcoma, serous, clear cell, undifferentiated adenocarcinoma, and and any mixed high risk histology.
  • Clinical stage 1 disease- no evidence of metastatic disease beyond the uterus by physical exam or preoperative imaging if performed.
  • Patients who have signed an approved informed consent.
  • Patients who will undergo surgery that includes a hysterectomy and bilateral pelvic and inframesenteric para-aortic lymphadenectomy via laparoscopy or robotic-assisted.

Exclusion

  • Women with grade 1 or 2 endometrioid adenocarcinoma
  • Patients with evidence of metastatic disease on preoperative imaging.
  • Patients with evidence of intraperitoneal metastatic disease intraoperatively (patients with suspicious retroperitoneal lymph nodes intraoperatively will still be included).
  • Patients with known allergy to iodine compounds
  • Pregnant patient.
  • Patients with previous retroperitoneal surgery.
  • Patients with previous history of pelvic/abdominal radiation.
  • Patients with recurrent endometrial cancer.
  • Any patient treated with neoadjuvant chemotherapy and/or radiation.

Key Trial Info

Start Date :

March 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2021

Estimated Enrollment :

156 Patients enrolled

Trial Details

Trial ID

NCT01886066

Start Date

March 1 2012

End Date

September 1 2021

Last Update

March 15 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sunnybrook Health Sciences Center

Toronto, Ontario, Canada, M4N3M5

2

University Health Network - Princess Margaret Hospital

Toronto, Ontario, Canada, M5T 2M9